TrialSignal
Clinical trial intelligence report
A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00529373
Status
TERMINATED
Phase
Phase III
Sponsor
Merck Sharp & Dohme LLC
Executive brief
Investment-Ready Snapshot
This clinical trial assessed the safety and efficacy of Odanacatib in reducing fracture risk among postmenopausal women with osteoporosis. The study involved a total of 16,071 participants, with a randomized, double-blind, placebo-controlled design over a duration of up to 10 years, including extensions.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00529373
Indication
Postmenopausal Osteoporosis
Modality
small molecule
Target
Odanacatib (MK-0822)
Intervention
Odanacatib, Placebo for Odanacatib, Vitamin D3, Calcium carbonate
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.